Eli Lilly announced on Tuesday that the government-sponsored clinical trial of its COVID-19 monoclonal antibody treatment has been paused due to a potential safety concern.
“Out of an abundance of caution, the ACTIV-3 independent data safety monitoring board (DSMB) has recommended a pause in enrollment,” Lilly spokeswoman Molly McCully said in an emailed statement. “Lilly is supportive of the decision by the independent DSMB to cautiously ensure the safety of the patients participating in this study.”
